Arrowhead Pharmaceuticals
Presencia
Arrowhead Pharmaceuticals es una de las ...
Arrowhead Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización ARWR (US).
Ejecutivos
Ver el organigrama con sus 29 ejecutivos principales
Biografías más buscadas en Arrowhead Pharmaceuticals
- Christopher Anzalone, President, Chief Executive Officer, Director
- Douglass Given, Chairman of the Board
- Mauro Ferrari, Director
Recientes movimientos de ejecutivos en Arrowhead Pharmaceuticals
- Javier San Martin, Chief Medical Officer, abandonará la empresa el 1 de feb.. de 2024 (noticia publicada el 23 de enero de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Arrowhead Pharmaceuticals.
Biotecnología
Arrowhead Pharmaceuticals tiene 2.282 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Endeavor BioMedicines acaba de anunciar una recaudación de fondos de 132 millones de dólares. (publicado el 25 de abril de 2024).
- Metsera acaba de anunciar una recaudación de fondos de 290 millones de dólares. (publicado el 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado el 19 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy - Arrowhead Pharmaceuticals, Inc.
- GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 | Arrowhead Pharmaceuticals Inc.
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease | Arrowhead Pharmaceuticals Inc.
- View more press releases Close
Redes sociales sobre Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Arrowhead Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Christopher Anzalone 
Llame a Arrowhead Pharmaceuticals al +1 626...
